These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 34421363)

  • 41. Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.
    Wang WJ; Li CF; Chu YY; Wang YH; Hour TC; Yen CJ; Chang WC; Wang JM
    Clin Cancer Res; 2017 Jan; 23(2):503-513. PubMed ID: 27435393
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1/2.
    Park BH; Lim JE; Jeon HG; Seo SI; Lee HM; Choi HY; Jeon SS; Jeong BC
    Oncotarget; 2016 Sep; 7(39):63870-63886. PubMed ID: 27564099
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance.
    Huang IP; Sun SP; Cheng SH; Lee CH; Wu CY; Yang CS; Lo LW; Lai YK
    Mol Cancer Ther; 2011 May; 10(5):761-9. PubMed ID: 21411714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Ferrocene Derivative Reduces Cisplatin Resistance in Breast Cancer Cells through Suppression of MDR-1 Expression and Modulation of JAK2/STAT3 Signaling Pathway.
    Noori S; Nourbakhsh M; Farzaneh S; Zarghi A
    Anticancer Agents Med Chem; 2020; 20(18):2285-2292. PubMed ID: 32767949
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells.
    Chen RJ; Ho YS; Guo HR; Wang YJ
    Toxicol Sci; 2008 Aug; 104(2):283-93. PubMed ID: 18448488
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of drug-resistant bladder carcinoma cells in vitro: impact on polychemotherapy with cisplatin, methotrexate and vinblastine (CMV).
    Rohde D; Brehmer B; Kapp T; Valdor M; Jakse G
    Urol Res; 1998; 26(4):249-57. PubMed ID: 9759998
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
    Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
    Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Canagliflozin inhibits p-gp function and early autophagy and improves the sensitivity to the antitumor effect of doxorubicin.
    Zhong J; Sun P; Xu N; Liao M; Xu C; Ding Y; Cai J; Zhang Y; Xie W
    Biochem Pharmacol; 2020 May; 175():113856. PubMed ID: 32061772
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling.
    Wu K; Wang B; Chen Y; Zhou J; Huang J; Hui K; Zeng J; Zhu J; Zhang K; Li L; Guo P; Wang X; Hsieh JT; He D; Fan J
    Cell Signal; 2015 Dec; 27(12):2515-23. PubMed ID: 26410305
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells.
    Kotoh S; Naito S; Yokomizo A; Kumazawa J; Asakuno K; Kohno K; Kuwano M
    Cancer Res; 1994 Jun; 54(12):3248-52. PubMed ID: 8205547
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers.
    Makhlin I; Zhang J; Long CJ; Devarajan K; Zhou Y; Klein-Szanto AJ; Huang M; Chernoff J; Boorjian SA
    BJU Int; 2011 Jul; 108(2 Pt 2):E84-90. PubMed ID: 21050361
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of STAT3 and Survivin silencing on the growth of human bladder carcinoma cells.
    Zhang B; Lu Z; Hou Y; Hu J; Wang C
    Tumour Biol; 2014 Jun; 35(6):5401-7. PubMed ID: 24519067
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder.
    Tyagi A; Chandrasekaran B; Kolluru V; Rai S; Jordan AC; Houda A; Messer J; Ankem M; Damodaran C; Haddad A
    Urol Oncol; 2019 Jul; 37(7):492-502. PubMed ID: 31006613
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel virosecurinine bivalent mimetics as potent reversal agents against P-glycoprotein-mediated multidrug resistance.
    Hou W; Meng Y; Xu XF; Huang ZX; Liu J; Wang ZY; Lin J; Chen WM
    Eur J Med Chem; 2019 Dec; 183():111726. PubMed ID: 31585275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Decreased APE-1 by Nitroxoline Enhances Therapeutic Effect in a Temozolomide-resistant Glioblastoma: Correlation with Diffusion Weighted Imaging.
    Cho HR; Kumari N; Thakur N; Vu HT; Kim H; Choi SH
    Sci Rep; 2019 Nov; 9(1):16613. PubMed ID: 31719653
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rictor-dependent AKT activation and inhibition of urothelial carcinoma by rapamycin.
    Wu MJ; Chang CH; Chiu YT; Wen MC; Shu KH; Li JR; Chiu KY; Chen YT
    Urol Oncol; 2012; 30(1):69-77. PubMed ID: 20207175
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway.
    Ryu K; Susa M; Choy E; Yang C; Hornicek FJ; Mankin HJ; Duan Z
    BMC Cancer; 2010 May; 10():187. PubMed ID: 20459702
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SPHK1 contributes to cisplatin resistance in bladder cancer cells via the NONO/STAT3 axis.
    Qin Z; Tong H; Li T; Cao H; Zhu J; Yin S; He W
    Int J Mol Med; 2021 Nov; 48(5):. PubMed ID: 34549307
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
    Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
    J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation.
    da Silva GN; Filoni LT; Salvadori MC; Salvadori DMF
    Pathol Oncol Res; 2018 Apr; 24(2):407-417. PubMed ID: 28577130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.